UWCCC Molecular Tumor Board Registry

University of Wisconsin (UW)

Status: Enrolling

Conditions: Hematologic Neoplasms; Solid Neoplasm

Treatments: Other: PMMTB (Precision Medicine Molecular Tumor Board)

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT03023202

SMPH\UWCCC\GENERAL (Other Identifier)

UW15068

1R37CA226526-01A1 (U.S. NIH Grant/Contract)

P30CA014520 (U.S. NIH Grant/Contract)

NCI-2019-06343 (Registry Identifier)

A533400 (Other Identifier)

Protocol Version 3/24/24 (Other Identifier)

2015-1370 (Other Identifier)

Details and patient eligibility

About

This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.

Enrollment: 10,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinically suspected or histologically confirmed solid or hematological malignancy
• Undergoing genetic testing of tumor
• Ability to understand written informed consent document
• Willingness to sign written informed consent document

Exclusion criteria

• Pediatric patients (age<18 years) will be excluded due to a lack of expertise on the molecular tumor committee

Trial design

10,000 participants in 1 patient group

PMMTB

Description:

This study of the PMMTB will include all patients \>= 18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor. All standard of care functions will be performed by standard procedures.

Treatment:

Other: PMMTB (Precision Medicine Molecular Tumor Board)